Bioer Technology

Based in China, Bioer Technology specializes in advanced biotechnology solutions, focusing on innovative diagnostic instruments and reagents to enhance laboratory efficiency and accuracy in health diagnostics. Bioer Technology, founded in 2002, operates from Hangzhou, China, and develops diagnostic solutions for healthcare. The company has executed one deal as of July 22, 2020, which involved raising funds from several investors. The founder's background is not specified.

Bioer Technology specializes in providing advanced biotechnology solutions, focusing primarily on diagnostic instruments and reagents. Their core offerings include a range of automated systems designed for molecular testing, enhancing laboratory efficiency and accuracy in diagnosing various health conditions. Their products are utilized predominantly in healthcare settings, including hospitals and independent laboratories, addressing critical diagnostic needs in infectious diseases and genetic disorders. The company emphasizes customer support and integration services to ensure effective implementation and utilization of their technologies.

Their products are marketed in several key regions including Asia-Pacific, Europe, and North America, catering to a diverse client base of healthcare professionals and institutions. The company generates revenue primarily through direct sales of its diagnostic instruments and accompanying reagents, structured around B2B transactions with healthcare providers and laboratories. Revenue streams are bolstered by partnerships with distribution channels that facilitate market penetration and accessibility of their products. Regular transactions typically involve bulk purchases of diagnostic equipment and reagents, with clients often engaging in contractual agreements for ongoing supply.

The pricing structure reflects the specialized nature of the products, with flagship instruments commanding premium pricing due to their advanced technology and critical role in healthcare diagnostics. Additionally, the company may offer service agreements to clients for maintenance and support, enhancing revenue stability. Looking forward, Bioer Technology aims to launch several new products designed to advance their diagnostic capabilities. The company plans to expand into new markets, targeting regions such as Southeast Asia and Europe by 2023.

Recent funding raised in July 2020 from investors including Guangdong Hybribio Biotech will support these initiatives, enabling the development of innovative products and expansion into these strategic geographic areas.